RB Starts ‘Supercharge’ Diet To Be ‘Leaner, More Agile’ In Consumer Health
This article was originally published in The Tan Sheet
Executive Summary
RB expects its “supercharge” cost-cutting strategy to yield as much as $228.5 million in annualized cost savings. The Mucinex marketer also says by 2020 it should compete almost exclusively in the consumer health, personal and household care markets.
You may also be interested in...
Consumer Health Care Products Industry Earnings Roundup
Pfizer Likes Consumer, But Not U.S. Tax Policy; Consumer Segment Stays At Reckitt, Rx To Leave; Merck Consumer Brands Strong With Division Sale Pending; Exchange Rates Deflate Bayer Growth; No Buyer’s Remorse At Sanofi; and Gummy Vitamin Business Soars For C&D
Flonase Switch Approved, Branded Nasal Allergy Spray Market Will Grow In 2015
Glaxo says Flonase Allergy Relief (fluticasone propionate 50 mcg spray) is the “first OTC nasal spray indicated for relief of all nasal and eye-related allergy symptoms.” The firm has not learned from FDA whether Flonase Allergy Relief will launch with market exclusivity.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.